Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study

NCT05626101 ·Status: RECRUITING ·Phase: NA

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

NCT05671900 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients

NCT06374914 ·Status: NOT_YET_RECRUITING

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

NCT06186414 ·Status: RECRUITING ·Phase: PHASE1

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

NCT01697306 ·Status: COMPLETED ·Phase: PHASE2

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

NCT03504163 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

NCT02625961 ·Status: COMPLETED ·Phase: PHASE2

Intravesical BCG vs GEMDOCE in NMIBC

NCT05538663 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

NCT04387461 ·Status: COMPLETED ·Phase: PHASE2

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

NCT04179162 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

NCT00234039 ·Status: COMPLETED ·Phase: PHASE2

A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

NCT07342517 ·Status: WITHDRAWN ·Phase: PHASE3

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

NCT02621151 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT03950362 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

NCT07189793 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NCT03732677 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

NCT06971614 ·Status: RECRUITING ·Phase: PHASE2

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

NCT04630730 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)

NCT02853305 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer

NCT04726735 ·Status: COMPLETED

Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab

NCT03212651 ·Status: COMPLETED ·Phase: PHASE2

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

NCT06187506 ·Status: RECRUITING ·Phase: PHASE2

Precise Neoadjuvant Chemoresection of Low Grade NMIBC

NCT06227065 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer

NCT00696579 ·Status: COMPLETED ·Phase: PHASE1/PHASE2